Skip to main content Accessibility help
×
Home

Effect of Long-acting Injectable Aripiprazole in Glucose and Lipids: A 1 Year Study

  • M. Juncal Ruiz (a1), O. Porta Olivares (a1), B. Fernández-Abascal Puente (a1), M. Gómez Revuelta (a2), R. Landera Rodríguez (a1), G. Pardo de Santayana Jenaro (a1), L. Sánchez Blanco (a1), M. Pérez Herrera (a1), D. Abejas Díez (a1) and J.L. García Egea (a3)...

Abstract

Introduction

Atypical anti-psychotics are associated with an impaired in glucose and lipids homeostasis.

Aims

To evaluate, the effect in lipids and glucose levels after switching to long-acting injectable (LAI) aripiprazole.

Methods

This was a prospective, observational, 1 year study carried out in 125 outpatients with schizophrenia who were clinically stabilized but a switching to another anti-psychotic was indicated. We measured basal levels of glucose and lipids at the time to start the study and 1 year after switching to LAI-aripiprazole.

Results

In basal analytic we observed these abnormalities: hyperglycemia (16.7%), high-levels of LDL-cholesterol (33.3%), low-levels of HDL-cholesterol (39%) and hypertrygliceridemia (22.2%). One year after switching to LAI-aripiprazole we found: glucose levels were normalized in all patients; levels of LDL-cholesterol were lower in 66.7% (in 33.3% levels were normalized) and they were higher in 16.7% (in 11% marked a change from normal to abnormal parameters); levels of HDL-cholesterol were lower in 23.3% and higher in 32.2% (in 11% levels were normalized); and finally, levels of tryglicerides were higher in 66.7% (in 8% marked a change from normal to abnormal parameters) and in 16.7% they were lower (in 7.3% levels were normalized).

Conclusions

LAI-aripiprazole has a beneficial effect in glucose and cholesterol levels. Although, it usually increases tryglicerides levels, only in seven cases there was a change from normal to abnormal parameters. Our study suggests that LAI-aripiprazol could be an alternative in patients with schizophrenia who have high levels of glucose and lipids related with atypical anti-psychotics treatment.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Effect of Long-acting Injectable Aripiprazole in Glucose and Lipids: A 1 Year Study
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Effect of Long-acting Injectable Aripiprazole in Glucose and Lipids: A 1 Year Study
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Effect of Long-acting Injectable Aripiprazole in Glucose and Lipids: A 1 Year Study
      Available formats
      ×

Copyright

Corresponding author

*Corresponding author.

Effect of Long-acting Injectable Aripiprazole in Glucose and Lipids: A 1 Year Study

  • M. Juncal Ruiz (a1), O. Porta Olivares (a1), B. Fernández-Abascal Puente (a1), M. Gómez Revuelta (a2), R. Landera Rodríguez (a1), G. Pardo de Santayana Jenaro (a1), L. Sánchez Blanco (a1), M. Pérez Herrera (a1), D. Abejas Díez (a1) and J.L. García Egea (a3)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

Effect of Long-acting Injectable Aripiprazole in Glucose and Lipids: A 1 Year Study

  • M. Juncal Ruiz (a1), O. Porta Olivares (a1), B. Fernández-Abascal Puente (a1), M. Gómez Revuelta (a2), R. Landera Rodríguez (a1), G. Pardo de Santayana Jenaro (a1), L. Sánchez Blanco (a1), M. Pérez Herrera (a1), D. Abejas Díez (a1) and J.L. García Egea (a3)...
Submit a response

Comments

No Comments have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *